This protein could interact with receptor tyrosine kinases on tumor cells, thereby activating the PI3K/AKT pathway, which is believed to be upregulated in patients from high-risk group, suggesting a target for therapeutic intervention. This evidence concerns the gene NTRK1 and neoplasm.